drugset / Trial / NCT01485731

Safety Study of Nelfinavir + Cisplatin + Pelvic Radiation Therapy to Treat Cervical Cancer

NCT01485731

Phase 1 Completed 8 enrolled University of Miami
NaSingle-groupOpen-labelTreatment

Summary

Nelfinavir will increase the efficacy of Cisplatin based chemo- radiation therapy for locally advanced cervical cancer.

Timeline

Start
2012-01
Primary completion
2015-02
Completion
2015-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Nelfinavir Other / unclassified 875 mg Oral
Background Cisplatin Other / unclassified 40 mg/m2 Intravenous

Indications